In continuation of my update on sitagliptin and metformin hydrochloride (HCl)
U.S. Food and Drug Administration (FDA) approved JANUMET® XR ((sitagliptin and metformin hydrochloride (HCl) ) extended-release) tablets, a new treatment for type 2 diabetes that combines sitagliptin, which is the active component of JANUVIA® (sitagliptin), with extended-release metformin. JANUMET XR provides a convenient once-daily treatment option for healthcare providers and patients who need help to control their blood sugar.
